| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Timtec is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boston BioCom is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Explora BioLabs, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Superhuman hair. Engineered from nature.